Yervoy Patient Assistance Basics
Yervoy (ipilimumab), made by Bristol Myers Squibb (BMS), offers copay assistance through the Bristol Myers Squibb Oncology Co-Pay Assistance Program. Eligible commercially insured patients pay as little as $5 per dose, up to an annual cap of $15,000–$25,000 depending on the drug and plan.[1]
What Counts as the Eligibility Limit?
Yes, eligibility ends when you hit the program's annual maximum assistance—typically $15,000 for Yervoy, covering copays, coinsurance, or deductibles. Once reached, you pay full out-of-pocket costs until the calendar year resets on January 1.[1][2] Household income must also stay under 800% of the federal poverty level (about $124,800 for a single person in 2024), and you need commercial insurance—not government plans like Medicare or Medicaid.[1]
How Do You Check Remaining Assistance?
Log into the BMS Access Support portal or call 1-888-757-2814. They track your year-to-date usage in real time and notify you when you're nearing the cap.[2]
What If You Hit the Cap Early?
Switch to free medicine via BMS Access, which requires income ≤500% FPL (about $75,300 for one person). Uninsured or underinsured patients may qualify for the Patient Assistance Foundation with no income cap but stricter criteria.[1][2] State programs or 340B clinics can fill gaps.
Does Insurance Type Affect Limits?
Commercial plans only; Medicare patients get no copay help due to federal anti-kickback laws. Medicare Savings Programs or Extra Help might cover costs instead.[1]
[1]: Bristol Myers Squibb Access & Reimbursement
[2]: DrugPatentWatch.com - Yervoy Patient Assistance